NCT01678573View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics of Abiraterone in Healthy Chinese Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Healthy
Interventions
DRUG

Treatment A: abiraterone acetate

250 mg/day tablet administered orally on Day 1 of each treatment period.

DRUG

Treatment B: abiraterone acetate

500 mg/day tablets administered orally on Day 1 of each treatment period.

DRUG

Treatment C: abiraterone acetate

1000 mg/day tablets administered orally on Day 1 of each treatment period.

Trial Locations (1)

Unknown

Beijing

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT01678573 - A Study to Evaluate the Pharmacokinetics of Abiraterone in Healthy Chinese Male Participants | Biotech Hunter | Biotech Hunter